Bristol Myers Squibb
BMY · NYSE · USD · Healthcare
Price
+1.7% since 20/04/20266 months · High $67.94 (-13.4%) · Low $52.30
What is happening
Bristol Myers Squibb has fallen 10% since its 6-week high on 08/09/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayHow deep is the dip?
- from the 6-week high-9.8%
Highest daily price: $65.21 on 08/09/2026 · reference of the assessment
- from the 3-month high-13.4%
Highest daily price in 3 months: $67.94 on 19/08/2026
- from the 52-week high-14.3%
Highest price in 52 weeks: $68.64 (Yahoo)
Marking places no order – it only helps you keep track.
Why is it down?
no visible trigger- ·From its 6-week high of $65.21 on 08/09/2026 the price fell 9.8% to $58.83.
- ·No clear news driver in the last 10 days.
- ·The market as a whole is calm, so this drop is specific to the company.
- ·Other Drug Manufacturers - General stocks we track are down only 4.0% on average, so this is mostly about the company. See all 47 in this sector →
A drop without a visible trigger is often selling pressure, not new facts. That is the kind of dip the engine looks for, but it is still a guess, not a promise.
Catalysts
1 h ago- News, last 10 days
- no recent news
- Next earnings
- 29/10/2026 · in 9 days
- Last report
- 30/07/2026 +27.7% vs estimate
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
About Bristol Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
- Headquarters:
- Princeton, United States
- 52-week range:
- $42.52 – $68.64
- Website:
- bms.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
